Vaginal News and Research

RSS

Immunity-enhancing probiotics may be the best line of defense for good health

Good bacteria, bad bacteria, billions of bacteria—sounds downright germy. But the truth is that research in gut health is germinating more insight into the role bacteria, also known as "probiotics," play in our overall health and wellness.

25 Nov 2010

Media outlets continue to follow major HIV/AIDS developments this week

Media outlets continued to track the major developments in HIV/AIDS this week, including: prevention research using an antiretroviral; new UNAIDS estimates of HIV/AIDS around the world; and Pope Benedict XVI's stance on condoms for HIV prevention.

25 Nov 2010

Important queries about PrEP, iPrEx trial for HIV infection

The results of the iPrEx PrEP effectiveness trial of once-daily TDF/FTC (brand name Truvada) in gay men, transgender women and other men who have sex with men are a landmark in HIV prevention research.

24 Nov 2010

HIV treatment drugs also help prevent HIV infection in high-risk men: Study

In a significant advance for HIV prevention research, a clinical trial confirms that the same drugs used for treating HIV can also help prevent HIV infection in the first place.

24 Nov 2010

iPrEx trial shows reduction in new HIV infections

Results of the world's first efficacy trial of an HIV-prevention approach called oral pre-exposure prophylaxis, or PrEP, were released online in the New England Journal of Medicine today.

24 Nov 2010

CONRAD congratulates Global iPrEx study team for HIV prevention trial

CONRAD is pleased to join in congratulating the Global iPrEx study team for their successful trial of oral tenofovir (TDF) with emtricitabine (FTC) for HIV prevention.

24 Nov 2010

Merck announces FDA Advisory Committee approval of GARDASIL for anal cancer and AIN treatment

Merck announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee has advised that the data presented support an indication for GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer and anal intraepithelial neoplasia (AIN) in both males and females 9 through 26 years of age.

18 Nov 2010

Hygeia completes HYG-102 preclinical studies for vulvar and vaginal atrophy, and age-related skin fragility

Hygeia Therapeutics, Inc. announced today the successful completion of a series of preclinical studies for HYG-102, their lead product for the treatment of vulvar and vaginal atrophy (VVA) and age-related skin fragility. HYG-102 is the lead biodegradable estrogenic candidate in a portfolio of 23 similar compounds licensed from the laboratory of Dr. Richard Hochberg of Yale University.

11 Nov 2010

Contraceptive, antiviral gel using bee venom wins 2010 Gates Foundation grant

A vaginal gel that affords both contraception and HIV protection using nanoparticles that carry bee venom is one of the bold, unconventional ideas that won a 2010 Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation.

10 Nov 2010

Forceps delivery can pose risk to mother and child

Forceps might be a better instrument than a vacuum cup for assisting a successful birth, but new mothers might experience more trauma and complications after a forceps delivery, according to a new review of studies.

10 Nov 2010

New York Times examines HIV prevention products undergoing clinical trials

The New York Times examines several products being studied in clinical trials that researchers hope will one day prevent sexual transmission of HIV. The newspaper describes the ongoing trials of a vaginal microbicide gel containing the antiretroviral tenofovir which was found to reduce the risk of HIV infection in women by 39 percent, writing, "[o]ther clinical trials will report their results in 2011 and 2012 and, if all goes well, researchers hope to have a product or two ready to enter the market by 2013."

10 Nov 2010

AAGL recommends vaginal or laparoscopic hysterectomies

Approximately 600,000 hysterectomies are performed in the United States annually to treat benign disorders of the pelvis. More than two-thirds are performed through an abdominal incision. In an evidence-based position statement published online today in The Journal of Minimally Invasive Gynecology, the AAGL, a medical specialty society of over 5,000 gynecologic surgeons, advocates the practice of performing these procedures vaginally or laparoscopically in a minimally invasive manner, thus reducing morbidity and facilitating a faster recovery period.

8 Nov 2010

People with SLE more likely to develop hematologic malignancies

People with systemic lupus erythematosus are 1.15 times as likely to develop cancer as the general population and more than 2.5 times as likely to develop hematologic malignancies, such as lymphoma and leukemia, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

CONRAD receives $5 million award from USAID

CONRAD, leaders in reproductive health and HIV prevention research, today announced a $5 million award from the US Agency for International Development (USAID). The grant will fund research and development of vaginal rings that are contraceptive and also prevent HIV and STI infections.

3 Nov 2010

African Americans more likely to have uterine cancer recurrence

African Americans are more likely to have a recurrence of uterine cancer despite undergoing a total hysterectomy or a hysterectomy followed by radiation therapy, according to researchers at Henry Ford Hospital in Detroit.

2 Nov 2010

Merck reports $342 million net income for 2010 third quarter

Merck & Co., Inc. today announced financial results for the third quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the third quarter of $0.85, which excludes purchase accounting adjustments, restructuring costs, merger-related expenses and a $950 million legal reserve.

29 Oct 2010

Tenofovir gel to prevent HIV transmission nearing approval

Anti HIV drug Tenofovir in its gel form is to be fast-tracked for approval by the US FDA. The announcement was made by Conrad, a nonprofit scientific organization based in Arlington, Virginia that works with reproductive health.

28 Oct 2010

CutisPharma receives U.S patent for suppository compounding

CutisPharma, Inc. today announced that it has received approval from the United States Patent and Trademark Office for its patent (US 7,815,929) regarding a method for the preparation, storage and dispensing of compounded suppositories.

28 Oct 2010

Reuters examines development progress of microbicide gel to prevent HIV

Reuters reports that the developers of a vaginal microbicide gel containing the antiretroviral tenofovir, which has been found to reduce "HIV infections in women by 39 percent," said the FDA last week granted fast-track approval designation to the gel.

28 Oct 2010

ENDOMETRIN Vaginal Insert offers effective luteal support in IVF procedures

Ferring Pharmaceuticals Inc. presented study results demonstrating that ENDOMETRIN (progesterone) Vaginal Insert provides effective luteal support compared to intramuscular (IM) progesterone-in-oil (PIO) in patients undergoing in vitro fertilization (IVF) using gonadotropin releasing hormone (GnRH) antagonist.

27 Oct 2010